GT Biopharma EBIT per Share
The EBIT per Share of GT Biopharma (GTBP) as of Oct 22, 2026 is -56.34 USD. In the previous year, EBIT per Share was -189.25 USD — a change of -70.23% (higher).
Get this data via API
Financial Data API
EBIT per Share
-56.34USD
YoY
-70.23%
Last updated:
The GT Biopharma EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 0.00USD | -100.00% |
| est | 10.01USD | +1,105.21% |
| est | 0.83USD | -111.09% |
| est | -7.49USD | -26.87% |
| est | -10.24USD | -81.83% |
| -56.34USD | -70.23% | |
| -189.25USD | -23.05% | |
| -245.94USD | -45.27% | |
| -449.41USD | +170.36% | |
| -166.23USD | +12,723.71% | |
| -1.30USD | -99.41% | |
| -221.46USD | -89.36% | |
| -2,080.44USD | +80.93% | |
| -1,149.87USD | -93.87% | |
| -18,748.00USD | +614.05% | |
| -2,625.59USD | +32.44% | |
| -1,982.50USD | -77.43% | |
| -8,785.00USD | -55.27% | |
| -19,640.00USD | +955.91% | |
| -1,860.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
GT Biopharma Stock analysis
Frequently Asked Questions about GT Biopharma stock
EBIT per Share of GT Biopharma is -56.34 USD in 2025.
EBIT per Share of GT Biopharma changed from -189.25 USD to -56.34 USD, representing a -70.23% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share GT Biopharma since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — GT Biopharma
All Key Metrics — GT Biopharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth